Are vaccines enough? To end COVID-19 we need more innovation – and more access

(Credit: Unsplash)

This article is brought to you thanks to the collaboration of The European Sting with the World Economic Forum.

Author: Arnaud Bernaert, Head, Shaping the Future of Health and Healthcare, World Economic Forum & Elissa Prichep, Project Lead Precision Medicine, World Economic Forum

  • COVID-19 will continue to cause illness and death in 2021 and beyond before vaccines are widely enough available and the virus is contained.
  • New alliances are needed to speed the journey of COVID-19 innovations from the scientist’s bench to the patient’s bedside across all countries.
  • Patent pooling seeks a business model that offers a more sustainable solution for increasing access to medical breakthroughs.

The world has arrived at a precarious juncture in the COVID-19 pandemic. The initial roll-out of vaccines has begun in a few countries, but infections and deaths are still rising globally, and it will be many months – likely more than a year in some developing countries – before vaccines are widely enough available and the virus is contained.

What that means is that COVID-19 will continue to cause a substantial amount of illness and death in 2021 and beyond. To help those who become infected with the virus, scientists, healthcare providers and governments are continuing to develop a diverse arsenal of new options for treating patients, both in the acute phase of their illness and for the growing list of chronic problems many survivors are suffering.

There is hope on the horizon. The US Food and Drug Administration is currently tracking more than 560 COVID-19 drug development programmes. But the challenge of taking a new medication from development in a lab to administration in a clinic is two-fold: first, there is the complex and expensive scientific lift of developing new interventions; second, there is the complicated task of making them accessible and affordable. For example, the most promising treatment advances to date involve monoclonal antibodies (mAbs), which are challenging to produce and distribute, currently in limited supply, and expensive – even in high-income settings.

Accelerating the journey from lab to bedside

The normal market mechanisms and incentive structures that guide the path of treatments from development to access – which are, arguably, sub-optimal in normal circumstances – are not suited to help combat a global pandemic. This is a situation that calls for new alliances that can speed the journey of COVID-19 innovations from the scientist’s bench to the patient’s bedside across all countries.

One positive development recently emerged that offers an example of multistakeholder collaboration. A united group of 21 companies representing a large portion of the world’s generic pharmaceutical manufacturers took a bold step. Though many are often competitors, they have pledged to work together to accelerate access to COVID-19 interventions in low- and middle-income countries via the non-profit Medicines Patent Pool (MPP).

MPP was established by Unitaid in 2010, and is a United Nations-backed public health organization that facilitates the development of and access to life-saving medications in low- and middle-income countries. Over the past decade, the organization has worked with product developers and generic manufacturers to secure agreements that delivered 15 billion doses of affordable breakthrough treatments for HIV and hepatitis C to 141 countries. MPP achieves this through an innovative model of negotiating voluntary agreements with patent holders to license their discoveries to a pool accessible to generic manufacturers capable of producing and distributing high-quality, affordable medical interventions.

The generic firms that have joined the MPP COVID-19 pledge have the capacity to deliver substantial amounts of conventional drugs, as seen in the last decade where the generic manufacturers have delivered over 15 billion doses of treatments through MPP licences.

Many of them are also building the infrastructure to produce more complex “biologics” – a category that includes the COVID-19 monoclonal antibody treatments.

It’s important for the world’s major pharmaceutical companies to join this effort as well. Among other things, patent pooling provides an orderly process for achieving consensus in addressing a familiar tension: generating private sector investments in biomedical innovation while ensuring equitable access to the products that emerge. This tension is especially evident today.

Balancing commercial industry imperatives with public health needs

Yet many pharmaceutical companies may worry about the implications of broadly licensing their IP to a patent pool. They include concerns that agreements designed to serve neglected populations might inadvertently erode market opportunities elsewhere. There also may be misgivings that there will be pressure to provide especially generous licensing terms for COVID-19 interventions, setting a precedent that would be applied to future negotiations for many other medical products.

But if all sides come to the table focused on the same goal – a fair solution for rapidly expanding access to COVID-19 innovations – they will find there is opportunity for crafting bespoke licences that balance commercial industry imperatives while favouring public health needs. Like the COVAX facility for improving access to vaccines and the World Health Organization’s (WHO) Access to COVID-19 Tools Accelerator (ACT A), it can help bridge a growing divide between different countries in securing the means to fight this pandemic. In fact, the WHO is looking to MPP to play a principal role in its COVID-19 Technology Access Pool (C-TAP). Health, pandemics, epidemics

What is the World Economic Forum doing about fighting pandemics?

The first human trial of a COVID-19 vaccine was administered this week.

CEPI, launched at the World Economic Forum, provided funding support for the Phase 1 study. The organization this week announced their seventh COVID-19 vaccine project in the fight against the pandemic.Davos 2019 – Press Conference: CEPI – Building a Global C…

The Coalition for Epidemic Preparedness Innovations (CEPI) was launched in 2017 at the Forum’s Annual Meeting – bringing together experts from government, business, health, academia and civil society to accelerate the development of vaccines against emerging infectious diseases and to enable access to these vaccines during outbreaks.

Coalitions like CEPI are made possible through public-private partnerships. The World Economic Forum is the trusted global platform for stakeholder engagement, bringing together a range of multistakeholders from business, government and civil society to improve the state of the world.

Organizations can partner with the Forum to contribute to global health solutions. Contact us to find out how.

Different from efforts that rely on charitable donations or philanthropic funding, patent pooling seeks a business model that offers a more sustainable solution for increasing access to medical breakthroughs.

Much as a range of treatment options are required to address COVID-19, a range of models should be employed to effectively expand access to these treatments. To be sure, negotiations over product licences, technology transfer arrangements and financing will be complex. Yet multiple stakeholders must come together to take this step if the world is to expand manufacturing, supply and ultimately access to life saving COVID-19 treatments.

the sting Milestones

Featured Stings

Can we feed everyone without unleashing disaster? Read on

These campaigners want to give a quarter of the UK back to nature

How to build a more resilient and inclusive global system

Stopping antimicrobial resistance would cost just USD 2 per person a year

Call to revitalize ‘language of the ancestors’ for survival of future generations: Indigenous chief

COVID-19 has hit Black Americans hardest. Healing this divide would lift the nation

In this ‘wildland’ farm in Britain, species thrive and yields are high

Parliament urges EU to take drastic action to reduce marine litter

ECB to people: Not responsible if you lose money on Bitcoin, your governments are

Trump in London poisons UK and Europe

A perfect storm is pushing children in sub-Saharan Africa into crisis

COVID-19: MEPs urge quick action to prevent “huge recession”

Why are the financial markets shivering again?

White Coat, Stained red

Intensified Al Qaeda and ISIL activity in Yemen ‘deeply worrying’, says UN Human Rights Office

A shortened EU Summit admits failures, makes risky promises

Commission proposes to purchase up to 300 million additional doses of BioNTech-Pfizer vaccine

Saudi Arabia: UN experts push for prompt release of women human rights defenders

Remittances could fall by $100 billion because of COVID-19 – here’s why that matters

Medical Devices Regulation: Commission welcomes Council support to prioritise the fight against coronavirus

These countries have the most powerful passports

INTERVIEW: Poverty, education and inclusion top new General Assembly President’s priority list

The right approach to addressing overcapacity problem from a Chinese perspective

Cybersecurity Act: build trust in digital technologies

‘Revved up climate action’ needed to counter ‘prolonged’ and deadly storms like Cyclone Idai: Guterres

A call for a new crop of innovators

Two rhythms and a sharpened pencil: how art can help us heal and make sense of the world

Young? You should work out the entrepreneurial heart before the mind

Ambassador Zhang Ming Attends the EP Debate on China-EU Relations and Answers Questions

Here are 10 of Nelson Mandela’s most inspirational quotes

At UN, youth activists press for bold action on climate emergency, vow to hold leaders accountable at the ballot box

From coca to cocoa: three lessons from Peru on how farmers can leave the drug trade behind

Want investors to care about natural resources? Put a price on them

Germany resists Macron’s plan for closer and more cohesive Eurozone; Paris and Berlin at odds

3 things the G20 can do to save the World Trade Organization

Schengen: MEPs ready for negotiations on temporary checks at national borders

EU should promote immigration as a humanitarian issue in order to provide a more permanent solution

EP Brexit Steering Group calls on the UK to overcome the deadlock

What just happened? 5 themes from the COP24 climate talks in Poland

Where do health literacy and health policy meet?

No tragedy for HIV educators

Digital Single Market: Cheaper calls to other EU countries as of 15 May

‘Digital divide’ will worsen inequalities, without better global cooperation

This is how New York plans to end its car culture

Robots, Artificial intelligence and Dentistry

The financial world upside-down: debt failure closer

COP24: Paris agreement remained alive but fragile while the EU attempts to slow down CO2 emissions for new cars

From DIY editing to matchmaking by DNA: how human genomics is changing society

Europe’s top court hears Intel and sends € 1.06 bn antitrust fine to review

How cocoa farming can help stop deforestation

Capital Markets Union: Commission to boost Europe’s capital markets

‘Eden bonds’: how rewilding could save the climate and your pension

China is picking up the fight against rare diseases

UN mobilizes in Rohingya camps to support babies born of rape; young mothers face stigma

To rebuild trust in the media, we must empower its consumers

Palliative Care in Children, why it is less known and why do we need to raise awareness more?

Deliver ‘significant results now’, UN General Assembly President tells COP25 climate conference

‘Perseverance is key’ to Iraq’s future, UN envoy tells Security Council

Ukraine: turning challenges into opportunities

A challenge for inclusion in the Dominican Republic’s health care services

State aid: Commission invites comments on simplified rules for State aid combined with EU support

Half of the world’s population lack access to essential health services – are we doing enough?

ILO warns of widespread insecurity in the global labour market

International Day of Cooperatives sets stage for long-standing production and consumption

More Stings?

Speak your Mind Here

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s